Olga Vlasenko

Olga Vlasenko

Auto-generated profile, based on publicly available information

Olga Vlasenko

V. N. Karazin Kharkiv National University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2009 in Technological and Economic Development of Economy
Verified
Journal Article
Closed access
OVOlga Vlasenko
Olga Vlasenko
SKSergey Kozlov
Sergey Kozlov
Dialectics of categories of risk and return are becoming increasingly important in business process. The knowledge of risk indices allows to shape the judgement and make a decision. The provided risk‐management method lets to make more reasonable and adequate managing decisions. The paper provides the substantiation of necessity of the enterprise risk level integral estimation. A calculation method for determining the probability curve of enterprise financial losses level has been worked out. Examples of risk curve use are given. Methodology of plotting the curve of possible loss probability or at least determination of regions and indices for acceptable, critical and catastrophic risk is seen as quite an efficient tool of management decision‐making by an organization. Santrauka Rizikos ir grąžos kategorijų dialektika tampa vis svarbesnė versle. Informacija apie rizikos rodiklius leidžia įvertinti ir priimti sprendimą. Siūlomas rizikos valdymo metodas leidžia priimti protingesnius ir tinkamesnius sprendimus. Straipsnyje aprašoma, kaip atlikti įmonės rizikos lygmens integralinį vertinimą. Sukurtas metodas, kuriuo galima nustatyti įmonės finansinių nuostolių lygmens tikimybės kreivę. Pateikti rizikos kreivės naudojimo pavyzdžiai. Metodologija, leidžianti grafiškai pavaizduoti galimų nuostolių tikimybės kreivę ar bent jau nustatyti priimtinos, kritinės ir katastrofiškos rizikos sritis ir rodiklius, yra gana efektyvus įrankis priimant efektyvius sprendimus organizacijoje.

17 May 2025 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
NDNadiia Demikhova
Nadiia Demikhova
LKLarysa Kuts
Larysa Kuts
SBSvitlana Bokova
Svitlana Bokova
EMEda Merisalu
Eda Merisalu
OVOlga Vlasenko
Olga Vlasenko
Interleukin-37 (IL-37) is a newly discovered anti-inflammatory cytokine from the IL-1 family that plays a key role in regulating both innate and adaptive immune responses. It is secreted in healthy tissues, reflecting a homeostatic function. Intracellularly, IL-37 suppresses diverse inflammatory signals in various cells, including dendritic cells, macrophages, epithelial cells, and endothelial cells. Although it has been studied in many conditions, such as autoimmune disorders, cancer, and cardiovascular disease, its specific role in kidney diseases remains relatively understudied. In this mini-review, we summarize current evidence on the biology of IL-37, with a focus on its relevance to kidney disease. We explore its molecular structure, patterns of expression, and the immunomodulatory mechanisms that may influence kidney diseases, including acute kidney injury, diabetic nephropathy, and autosomal dominant polycystic kidney disease. We also discuss the challenges of translating IL-37-based therapies into clinical practice and highlight key areas for future research aimed at unlocking its potential in the treatment of kidney diseases.

11 June 2026
Verified
Journal Article
Open access
ORO. H. Reznichenko
O. H. Reznichenko
KVK. V. Vovk
K. V. Vovk
LSL. L. Sherstiuk
L. L. Sherstiuk
OVO. O. Vlasenko
O. O. Vlasenko
HKH. S. Kratenko
H. S. Kratenko
Dyslipidemia is a pathological condition characterized by abnormal concentrations of lipids and lipoproteins in blood plasma, including increased levels of total cholesterol, low-density lipoproteins, and triglycerides, decreased levels of high-density lipoproteins, or a combination thereof. Dyslipidemias can be primary (genetically determined) or secondary, resulting from other diseases or environmental factors, and represent one of the key modifiable risk factors for atherosclerosis and cardiovascular disease. Aim. To analyze current evidence on dietary recommendations for dyslipidemia and evaluate their effectiveness in correcting the lipid profile. Materials and methods. A search was conducted in PubMed, Embase, ResearchGate, Crossref databases using the following keywords: dyslipidemia, cardiometabolic disorders, metabolic syndrome, cardiovascular diseases, dietary nutrition, lipid biomarkers and lifestyle. Results. Given the growing prevalence of cardiometabolic disorders, dietary interventions that effectively reduce these risks are gaining importance. Alongside pharmacological therapy, dietary correction and lifestyle modification are recommended as first-line measures. Thus, incorporating specific bioactive food compounds with proven cardioprotective properties into the diet has demonstrated meaningful clinical benefit. The strongest evidence for dyslipidemia correction supports the Mediterranean diet, a high-fiber diet, an anti-inflammatory diet, and plant-based dietary patterns, etc. The Mediterranean diet, rich in fruits, nuts and olive oil, vegetables, legumes, whole grains, with moderate consumption of fish and poultry and limited intake of red and processed meat has shown positive effects on cardiometabolic outcomes. Through its content of soluble and insoluble fiber, monounsaturated fatty acids (oleic acid), polyunsaturated fatty acids including omega-3, polyphenols (oleuropein, resveratrol), phytosterols, flavonoids, catechins, and carotenoids, it exhibits anti-inflammatory and antioxidant properties, improves serum lipid levels and insulin sensitivity, and lowers blood pressure. Conclusions. Dietary interventions represent the first line of non-pharmacological lipid profile correction. Evidence supports the effectiveness of reducing saturated and trans-fat intake while increasing the proportion of unsaturated fatty acids, particularly mono- and polyunsaturated fatty acids. The Mediterranean and DASH dietary patterns, combined with weight control, regular physical activity, and lifestyle modification, provide the greatest positive effect on the lipid profile.

30 June 2025 in Karazin Journal of Immunology
Verified
Journal Article
Open access
PDF file
LBL.V. Bieliaieva
L.V. Bieliaieva
KVK.V. Vovk
K.V. Vovk
LSL.L. Sherstiuk
L.L. Sherstiuk
OVO.O. Vlasenko
O.O. Vlasenko
Background. Primary immunodeficiencies are a large and heterogeneous group of hereditary disorders characterized by disorders in the development, functioning or regulation of the immune system. The etiology of the vast majority of primary immunodeficiencies is directly related to genetic defects that may have different types of inheritance. Thanks to significant advances in molecular genetics and genomics in recent decades, a growing number of genes (currently more than 450) have been identified and characterized, with mutations leading to the development of these diseases. Primary immunodeficiencies demonstrate significant clinical and genetic heterogeneity. Purpose – to review the key genetic defects, their mechanisms of influence on the immune system and the relationship with clinical manifestations of primary immunodeficiencies. Materials and methods. The selection of publications was performed using the PubMed, Clinical Key Elsevier and Google Scholar databases, which covered the results of original research and review papers. At the first stage, we searched the literature using the following Keywords: primary immunodeficiencies, genetic defects, monogenic diseases, genetic polymorphism, immune system, clinical manifestations, mechanisms of development, molecular diagnostics, gene therapy. At the second stage, abstracts of articles were studied and publications that did not meet the study criteria were excluded. At the third stage, the full texts of the selected articles were studied for compliance with the criteria for inclusion in the list of references and relevance. Results. The review takes an in-depth look at the key genetic defects underlying primary immunodeficiencies (the review is also devoted to the genetic basis of combined immunodeficiencies). The analysis of the genetic basis of combined immunodeficiencies has revealed significant heterogeneity, covering a wide range of mutations in genes encoding proteins critical for the development and functioning of T- and B-lymphocytes. The presence of specific mutations correlates with specific clinical phenotypes and disease severity. The findings emphasize the crucial importance of a genetic diagnosis for patients. In particular, a genetic diagnosis allows for personalized approaches to the treatment algorithm. Further research on genetic markers of immunodeficiencies is essential for the development of new diagnostic tools and innovative treatments. Conclusions. The review of the category of combined immunodeficiencies demonstrates significant genetic and phenotypic heterogeneity. Identification of a specific genetic defect is fundamental for understanding the pathogenesis, accurate diagnosis and selection of optimal treatment.

10 June 2026 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
OCO. Chernatska
O. Chernatska
NDN. Demikhova
N. Demikhova
OVO. Vlasenko
O. Vlasenko
IDI. Dehtyarova
I. Dehtyarova
ADA. Demikhov
A. Demikhov
Physical activity (PA) is a non-pharmacological intervention that may improve cardiovascular risk, functional capacity, muscle strength, inflammation, and quality of life in patients with chronic kidney disease (CKD). However, practical use of PA remains limited because exercise prescription should differ according to CKD stage, dialysis status, comorbidity burden, and baseline physical capacity. The aim of this narrative review was to summarize mechanisms linking PA and CKD, evaluate clinical evidence for aerobic, resistance, balance, and low-intensity exercise, and formulate practical recommendations for non-dialysis and dialysis patients. The reviewed evidence supports regular aerobic activity, resistance and balance training, and reduction of sedentary time in clinically stable non-dialysis CKD. Expected benefits include better cardiorespiratory fitness, muscle performance, endothelial function, inflammatory profile, and physical functioning. For dialysis patients and patients with advanced CKD, individualized low-intensity activity, especially a home-based walking program with gradual progression, is a reasonable and safer starting strategy. Exercise should be prescribed as part of CKD care, monitored by symptoms, Borg scale, heart-rate response, gait speed, and the six-minute walk test.